4.8 Article

The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling

Journal

CURRENT BIOLOGY
Volume 15, Issue 19, Pages 1762-1767

Publisher

CELL PRESS
DOI: 10.1016/j.cub.2005.08.050

Keywords

-

Funding

  1. NCI NIH HHS [CA46595] Funding Source: Medline
  2. NHGRI NIH HHS [HG00041] Funding Source: Medline

Ask authors/readers for more resources

The viability of vertebrate cells depends on a complex signaling interplay between survival factors and cell-death effectors. Subtle changes in the equilibrium between these regulators can result in abnormal cell proliferation or cell death, leading to various pathological manifestations [1, 2]. Death-associated protein kinase (DAPK) is a multidomain calcium/calmodulin (CaM)-dependent Ser/Thr protein kinase with an important role in apoptosis regulation and tumor suppression [3-6]. The molecular signaling mechanisms regulating this kinase, however, remain unclear. Here, we show that DAPK is phosphorylated upon activation of the Ras-extracellular signal-regulated kinase (ERK) pathway [7]. This correlates with the suppression of the apoptotic activity of DAPK. We demonstrate that DAPK is a novel target of p90 ribosomal S6 kinases (RSK) 1 and 2, downstream effectors of ERK1/2 [8-11]. Using mass spectrometry, we identified Ser-289 as a novel phosphorylation site in DAPK, which is regulated by FISK. Mutation of Ser-289 to alanine results in a DAPK mutant with enhanced apoptotic activity, whereas the phosphomimetic mutation (Ser289Glu) attenuates its apoptotic activity. Our results suggest that RSK-mediated phosphorylation of DAPK is a unique mechanism for suppressing the proapoptotic function of this death kinase in healthy cells as well as Ras/Raf-transformed cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available